Invivyd Completes Enrollment for Phase 3 DECLARATION Trial Evaluating VYD2311 for COVID-19 Prevention

**FOR IMMEDIATE RELEASE**

Invivyd recently announced the completion of enrollment for its Phase 3 DECLARATION clinical trial, which is evaluating VYD2311, an investigational antibody intended for the prevention of COVID-19. The company has upsized the trial.

The DECLARATION trial is a pivotal study designed to assess the efficacy and safety of VYD2311 as a preventative measure against COVID-19. VYD2311 is an investigational antibody. The completion of enrollment marks a significant milestone in the clinical development program for VYD2311.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI